Your browser doesn't support javascript.
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Aguirre, Clara; Meca-Lallana, Virginia; Barrios-Blandino, Ana; Del Río, Beatriz; Vivancos, Jose.
  • Aguirre C; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Princesa, Madrid, Spain. Electronic address: claraguih@hotmail.com.
  • Meca-Lallana V; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Princesa, Madrid, Spain.
  • Barrios-Blandino A; Department of Infectious Diseases, Hospital Universitario La Princesa, Madrid, Spain.
  • Del Río B; Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Princesa, Madrid, Spain.
  • Vivancos J; Department of Neurology, Hospital Universitario La Princesa, Madrid, Spain.
Mult Scler Relat Disord ; 44: 102250, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-506088
ABSTRACT
The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS) treatment, acts blocking α4-integrin. We report a MS patient treated with natalizumab who develops COVID-19, with excellent recovery and repeated negative results in 5 consecutive microbiological studies. We postulate this may be due to the blockade of integrins induced by natalizumab.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Natalizumab / COVID-19 / Immunologic Factors / Multiple Sclerosis Type of study: Case report / Prognostic study Topics: Long Covid Limits: Adolescent / Humans / Male Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Natalizumab / COVID-19 / Immunologic Factors / Multiple Sclerosis Type of study: Case report / Prognostic study Topics: Long Covid Limits: Adolescent / Humans / Male Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article